Propionic acidaemia is an inheirited metabolic condition caused by a lack of a liver enzyme, which leads to accumulation of toxic compounds. In a first-in-human trial, a therapeutic messenger RNA drug (mRNA-3927) led to restored enzyme activity, was well tolerated and showed a promising dose-dependent reduction of potentially life-threatening clinical events.